Skip to main content
Biocure Technology Inc. logo

Biocure Technology Inc. — Investor Relations & Filings

Ticker · CURE.X LEI · 529900KSL59IBBDYBU95 CSE Manufacturing
Filings indexed 149 across all filing types
Latest filing 2025-05-03 Audit Report / Informat…
Country CA Canada
Listing CSE CURE.X

About Biocure Technology Inc.

https://biocuretech.com/

Biocure Technology Inc. is a biopharmaceutical company specializing in the development and commercialization of advanced biological medicines. The company's core focus areas include proprietary CAR T-cell therapies designed to treat various cancers, such as leukemia, lung, and breast cancer. Concurrently, Biocure is engaged in the development and commercialization of major biosimilar pharmaceutical products, aiming to improve the accessibility of complex biological treatments. Furthermore, the company pursues novel, highly-efficacious therapies for severe diseases caused by RNA viruses where significant unmet medical needs exist.

Recent filings

Filing Released Lang Actions
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 1% confidence The document is clearly an Independent Auditor’s Report issued by Dale Matheson Carr-Hilton Labonte LLP, including their opinion, basis for opinion, key audit matters, and the audited consolidated financial statements for the years ended December 31, 2024 and 2023. This is a standalone audit report rather than a full annual report or an announcement of results. Therefore, it fits the Audit Report / Information category. FY 2024
2025-05-03 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a non-brokered private placement financing (capital raise) of units comprising shares and warrants, detailing the terms, use of proceeds, and related party exemptions. This is clearly a financing update rather than an earnings report, management change, or regulatory filing. It fits the “Capital/Financing Update” category.
2025-04-22 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a news release announcing a non‐brokered private placement to raise $200,000 through the sale of new common shares, including pricing, insider participation, exemptions, and use of proceeds. This is clearly an update on the company’s financing activity (fundraising), fitting the Capital/Financing Update category (CAP).
2024-12-20 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2024-11-14 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2024-11-14 English
Interim MD&A - English.pdf
Regulatory Filings
2024-11-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.